Tags : Acquires

STADA Expands its Specialty Footprint with the Acquisition of Lobsor

Shots:   STADA acquires Lobsar and its innovative therapy to foster its footprints in specialty pharmaceuticals. The acquisition complements STADA’s portfolio and expertise in the treatment of late-stage Parkinson’s disease With the acquisition, STADA gain rights to a triple fixed combination (levodopa/carbidopa/ entacapone) delivered via modern pump technology, already launched in Nordic countries Levodopa, carbidopa and […]Read More

Roche Acquires Inflazome for ~$450M

Shots: Inflazome to receive $450.31M as up front and is eligible to receive additional contingent payments based on the achievement of certain predetermined milestones The acquisition allows the Roche to get full rights to Inflazome’s portfolio consisting of pre/ clinical orally available small molecule NLRP3 inhibitors Roche will further advance the NLRP3 inhibitors across a […]Read More

AstraZeneca Acquires Dogma Therapeutics’ Oral PCSK9 Inhibitor Program

Shots: Dogma to receive upfront along with global regulatory and commercial milestones. AstraZeneca to get the rights to an orally active drug inhibiting PCSK9, offering a patient-friendly alternative to current cholesterol-lowering therapies that are delivered via a needle The agreement allows the AstraZeneca to develop the first small molecule, orally bioavailable PCSK9 inhibitor for patients […]Read More

ACADIA Acquires CerSci Therapeutics for $52.5M

Shots: ACADIA acquires all outstanding shares of CerSci for $52.5M. CerSci may receive up to $887M as development, commercialization milestones along with royalties on sales The acquisition will boost ACADIA’s clinical pipeline with the addition of non-opioid pain therapies including CerSci’s lead candidate ACP-044 ACP-044 has demonstrated a promising effect in the P-I study with an […]Read More

Bionano Genomics Acquires Lineagen to Facilitate the Clinical Adoption of

Shots: Lineagen to receive $9.6M consisting of 6,167,510 shares of Bionano’s common stock, ~ $1.7M in cash and assumption of ~$2.9M in liabilities. The acquisition complements Binano by adding leading cytogeneticists, genetic counselors, laboratory operations and billing experts, clinical commercialization experts, and payor contracts The acquisition expands Bionano’s Saphyr genome imaging platform by adding Lineagen’s […]Read More

Boehringer Ingelheim Acquires GST to Boost its Stem Cell Capabilities

Shots: Boehringer Ingelheim has acquired Global Stem cell Technology (GST) focusing to strengthen its portfolio capabilities to accelerate innovation and growth The acquisition follows two years of partnership b/w the companies that brought the first-ever registered stem cell-based veterinary medicine (Arti-Cell Forte) in the EU The acquisition of GST will accelerate the development pipeline of […]Read More

Royalty Pharma Acquires PTC’s Royalty Interest in Risdiplam for $650M

Shots: PTC Therapeutics to receive $650M as upfront in cash in exchange for ~43% of the risdiplam royalties, up to a specified amount while PTC maintains the majority of the risdiplam royalty stream and retains all economics associated with up to ~$400M in remaining regulatory and commercial milestones The collaboration enables PTC to further develop […]Read More

Foundation Medicine Acquires Lexent to Expand its Liquid Biopsy Platforms

Shots: Foundation Medicine acquires Lexent to accelerate the Foundation’s R&D strategy and expand its existing liquid biopsy platforms to advance cancer care for patients. The acquisition will boost Foundation Medicine’s capabilities to support adaptive clinical trial designs and accelerate therapeutic development in both early/ late-stage disease The addition of Lexent’s technology to Foundation’s portfolio of […]Read More

Roche Acquires Stratos Genomics to Advance the Development of Nanopore

Shots: Roche has acquired Stratos Genomics to facilitate the development of its nanopore sequencer to provide the healthcare community and ultimately patients with faster and cheaper clinical diagnostic testing The acquisition provides Roche access to Stratos Genomics unique chemistry, Sequencing by Expansion (SBX). The addition of the SBX chemistry is expected to provide the HCPs […]Read More